Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection.

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a …

Learn more about Zepbound® (tirzepatide), an injection treatment for adults with obesity and moderate-to-severe obstructive sleep apnea.

Zepbound® is available in an injectable single-dose pen and a single-dose vial. Learn about dosing, how to inject, and more.

Monitor patients treated with Zepbound for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior. Discontinue Zepbound in patients who experience suicidal thoughts or behaviors. Avoid Zepbound in patients with a history of suicidal attempts or active suicidal ideation.

Usa Zepbound exactamente como tu profesional de la salud te lo indique. Usa Zepbound con una dieta baja en calorías y más actividad física. Zepbound se aplica debajo de la piel (subcutáneamente) del estómago (abdomen), muslo o parte superior del brazo. Usa Zepbound 1 vez a la semana, a cualquier hora del día.

Zepbound® comes in multiple dosing forms including the Zepbound® Pen and the Zepbound® Vial. Learn about dosing forms for pen & vial, how to dose and helpful tips.

Card expires and savings end on 12/31/2025 for patients with commercial drug insurance with coverage for Zepbound and on 06/30/2025 for patients with commercial drug insurance who do not have coverage for Zepbound.

Learn more about Zepbound's® (tirzepatide) weight reduction (WR) efficacy and safety clinical data in adults with obesity.

Learn more about Zepbound's® (tirzepatide) efficacy and safety clinical data for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.